授权合作获益、尚无产品上市,和誉医药首度实现全年盈利

新京报
05 Mar

和誉医药近日披露2024年业绩,报告期内实现营收5.04亿元,凭借授权款和里程碑付款,尚无产品上市的和誉医药首度实现全年盈利,年内利润为2830.2万元。和誉医药表示,目前有充裕的在手现金储备,现金及银行结余约19.59亿元。  授权合作驱动业绩增长  和誉医药为临床阶段的生物制药公司,其研发管线由19种主要用于肿瘤的候选药物组成,以小分子为核心,专注于肿瘤精准治疗及肿瘤免疫治疗,其中12个候选...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10